Thus, expression of PD-1 indicates tumor reactive T cells and by blocking PD-1/PD-L1, specific antitumor activity is unleashed initially at periphery and later in the tumor as CTLs move from blood stream into the TME. This evidence concerns the gene PDCD1 and neoplasm.